South-East Asia Regional Certification Commission for Polio Eradication (SEA-RCCPE)

Report of the Fifth Meeting Malé, Maldives, 4-7 March 2013



Regional Office for South-East Asia

SEA-Immun-75 Distribution: General

South-East Asia Regional Certification Commission for Polio Eradication (SEA-RCCPE)

Report of the Fifth Meeting Malé, Maldives, 4–7 March 2013



Regional Office for South-East Asia

© World Health Organization 2013

All rights reserved.

Requests for publications, or for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – can be obtained from Publishing and Sales, World Health Organization, Regional Office for South-East Asia, Indraprastha Estate, Mahatma Gandhi Marg, New Delhi 110 002, India (fax: +91 11 23370197; e-mail: publications@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication does not necessarily represent the decisions or policies of the World Health Organization.

Printed in India

Maps disclaimer

The boundaries and names shown and the designations used on the maps contained in this document do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Contents

		Page
Acr	onyms	v
1.	Introduction	1
2.	Global progress towards polio eradication	2
3.	Recommendations from the meeting of the Independent Monitoring Board, Global Polio Eradication Initiative, London, 29–31 October 2012	3
4.	Progress of polio eradication in the South-East Asia Region	4
5.	Recommendations for NCCPE	5
6.	Recommendations for the WHO Secretariat	11

Annexes

1.	Agenda	14
2.	List of participants	15

Acronyms

AFP	acute flaccid paralysis
cVDPV2	circulating vaccine derived polio virus (type 2)
GBS	Guillain–Barré Syndrome
GPEI	Global Polio Eradication Initiative
ICMR	Indian Council of Medical Research
IMB	Independent Monitoring Board
LGA	local government area
NCCPE	National Certification Committee for Polio Eradication
NPSP	National Polio Surveillance Project
OPV	oral polio vaccine
RI	routine immunization
SEA-RCCPE	South-East Asia Regional Certification Commission for Polio Eradication
SIA	supplementary immunization activity
SEARO	
	Regional Office for South-East Asia
VDPV	Regional Office for South-East Asia vaccine derived poliovirus
	0

1. Introduction

The fifth meeting of the South-East Asia Regional Certification Commission for Polio Eradication (SEA-RCCPE) was held from 4 to 7 March 2013 in Malé, Maldives. Dr Supamit Chunsuttiwat of Thailand chaired the meeting. In addition to the SEA-RCCPE members, there were representatives from WHO headquarters, Regional office and India Country office (NPSP), NCCPE, and the India-Laboratory Taskforce. See annexes 1 and 2, respectively for the agenda and list of participants of the meeting.

The fourth meeting of the SEA-RCCPE held in Bangkok, Thailand from 18 to 20 December 2012, studied the preliminary documentation submitted by the India-NCCPE. The following conclusions and recommendations were made:


- (1) Based on the information presented by India on the first block of 19 "low-risk" states and union territories, the SEA-RCCPE believed that the AFP surveillance system in these areas is capable of detecting wild and vaccine-derived polioviruses. The SEA-RCCPE was convinced that the last case of wild virus was detected in 2007, and that there was no wild virus circulating in these areas.
- (2) SEA-RCCPE still had concerns about population immunity and the accumulation of susceptible population due to poor routine immunization coverage and low coverage during national immunization days and supplementary immunization activities.
- (3) Additional efforts were needed to ensure that high population immunity in these 19 states and union territories was maintained.

The fifth meeting of the SEA-RCCPE was convened for NCCPE and the India Laboratory Task Force supported by NPSP to present certification data including updated phase-1 laboratory containment plans. The Commission was also provided with global and regional polio eradication overviews.

2. Global progress towards polio eradication

Significant progress was made by the global polio eradication programme in 2012, though polio remained endemic in Afghanistan, Nigeria and Pakistan. India was removed from the list of endemic countries on 25 February 2012 after being polio-free for more than a year. At the Sixty-fifth World Health Assembly in May 2012, Member States declared that "completion of polio eradication is a programmatic emergency for global public health."

Figure 1. Global distribution of wild poliovirus, 1 January—5 March 2013



There were significantly fewer wild poliovirus cases in Afghanistan, Chad and Pakistan in 2012 compared to 2011. However, compared to 2011, Nigeria showed an increase and was the only country to report type-3 wild poliovirus cases during the last nine months of 2012. Overall in 2012, Afghanistan reported 37 cases, Chad 5, Nigeria 122 and Pakistan 58. The Khyber Pakhtumkwa (KP) and Federally Administered Tribal Areas (FATA) of Pakistan continue to be areas of concern and reservoirs for the poliovirus. In 2012, there were circulating vaccine-derived poliovirus (cVDPV) type 2 case outbreaks in Afghanistan, Chad, Kenya, Nigeria, Pakistan and Somalia and two cases of type 3 cVDPV in Yemen.

Tragically, in December 2012, nine polio vaccinators were shot and killed while vaccinating children in Pakistan near KP, Peshawar and Karachi. Again in February 2013, nine polio vaccinators were shot and killed in Nigeria's northern state of Kano. The impact of these senseless acts of violence in Pakistan and Nigeria is still not clear, but polio vaccination activities in these areas are expected to be negatively impacted.

3. Recommendations from the meeting of the Independent Monitoring Board, Global Polio Eradication Initiative, London, 29–31 October 2012

The Independent Monitoring Board (IMB) was formed in 2010 to review and monitor progress on the Global Polio Eradication Initiative (GPEI). The main conclusions of the IMB at its meeting in London, 29—31 October 2012 included the recognition that there were fewer polio cases in 2012 than ever in history, with only 94 districts in four affected countries. The commitment to polio eradication is an unprecedented priority, mostly due to the WHO declaration of polio as a global public health emergency. The goal of eradicating polio was not achieved by 2012, but prospects of attaining the goal are brighter than ever. There continues to be a high risk of more cases in more countries in 2013, underscoring the high priority to reduce risks and maintain progress toward eradication. Ten specific comments and recommendations were made:

- (1) International Health Regulations (IHR) should designate an expert review committee to urgently issue, by May 2013, a standing recommendation to introduce pre-travel vaccination and vaccination checks in Afghanistan, Nigeria and Pakistan. No citizen from an endemic country should be allowed into any country without a valid vaccination certificate.
- (2) Leaders and partners of endemic and infected countries should establish five priority low season goals to be achieved by April

2013. An update on priority goals and a progress report is to be presented at the IMB meeting in May 2013.


- (3) An analysis of the relationship between the number and quality of SIAs should be completed to guide decisions about the optimum interval between rounds.
- (4) All district and local government-level polio committees and task forces in endemic and infected countries should include a parent, representing all parents in the district.
- (5) Every opportunity should be taken to pair other health interventions with the administration of polio vaccine.
- (6) A report on global vaccine supply should be provided at each of the future meetings of the IMB.
- (7) GPEI will establish a systematic process to capture lessons learnt; some regional efforts are ongoing, for example, AFRO is planning to put together a best practices document.
- (8) Intensive polio watch will be set up in polio-free countries at the highest risk of importation and outbreaks. WHO should issue action plans for strengthening vaccination coverage and surveillance in these countries.
- (9) India should plan for a simulation exercise to test readiness for emergency response, to begin in a randomly selected group of districts in mid-2013.
- (10) A live web-cam video feed will be broadcast online from the Nigeria Emergency Polio Operations Center, allowing IMB and other partners to observe and provide input at any time.

4. Progress of polio eradication in the South-East Asia Region

The South-East Asia Region has been polio-free for over two years. India has achieved its longest polio-free period ever with the last wild poliovirus case reported on 13 January 2011 from Howrah, West Bengal (Figure 1). The historically polio-endemic states of Bihar and Uttar Pradesh have remained free of polio for more than two years. The last type-2 polio case was reported from Aligarh, Uttar Pradesh in August 1999 while the last

type-3 polio case was reported from Pakur, Jharkhand in October 2010. Importation of poliovirus from neighbouring and distant countries continues to be a risk.

Figure 2: Status of polio eradication in the South-East Asia Region



* BAN – 2006 and NEP – 2010: WPV outbreaks from India importations **Myanmar – 2007 type1 poliovirus outbreak in province Rakhine (district Maungdaw) bordering Bangladesh.

5. Recommendations for NCCPE

Bangladesh, Bhutan, India (block II), Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste submitted 2012 annual updates for the RCCPE to review. The report from the Democratic People's Republic of Korea is pending.

The SEA-RCCPE reviewed each country report and made specific recommendations to improve the national certification process and documentation. General recommendations for all programmes are followed by National Certification Committee-specific recommendations (Tables 1 and 2).

General programme recommendations:

- (1) Overall population immunity must be ensured through high routine immunization coverage and high quality SIAs to prevent circulation after importation of poliovirus and emergence of vaccine derived polio viruses (VDPVs). The minimum coverage at the national, state and district levels should be 90%.
- (2) Functioning of a uniform and highly sensitive AFP surveillance system to verify the absence of poliovirus and guarantee the timely detection and response to importations and VDPVs should be ensured.
- (3) All National Certification Committees (NCCs) should review with their respective national health authorities the current WHO recommendations for polio vaccination requirement for travellers. Regardless of age, all travellers to countries or areas with current or recent poliovirus transmission, or those who plan to attend mass gatherings with the risk of exposure to infected persons should be fully vaccinated (per International Health and Travel) against polio before departure.
- (4) All NCCs should advocate with their respective governments to support the IMB's recommendation on the use of the IHR to require polio immunization for travellers and to urge the WHO Director-General to move forward with the implementation of this recommendation prior to the Sixty-sixth World Health Assembly in May 2013.

General recommendations for NCC annual reports:

- (1) An accurate explanation of the population immunity throughout the country that includes a description of routine immunization coverage and any additional supplementary immunization activities (SIAs) should be ensured.
- (2) Any immunity gaps (OPV3 coverage ≤90% national, ≤80% district) should be thoroughly described, including any immunization activities planned to prevent circulation after importation of poliovirus and/or the emergence of VDPVs.
- (3) It must be ensured that a detailed description of any process or impact surveillance indicator that is below global standards is provided in the report.

- (4) A clear description of cross-border areas and any bilateral/ multilateral collaborations to synchronize immunization and surveillance activities should be ensured.
- (5) An updated copy of the national outbreak and preparedness plan that includes source of vaccine (self-procurement, UNICEF) and licensure status (mOPV, bOPV, tOPV) should be provided as an annex to the annual report.
- (6) A description of plans to test outbreak and preparedness plan (i.e., simulation exercises) should be provided.
- (7) All graphs/charts and maps should have clear legends.
- (8) The Guillain–Barré Syndrome (GBS) rate should be calculated as part of the non-polio AFP rate.
- (9) A copy of the updated phase-1 laboratory containment documents should be provided as an annex to the 2012 annual report.
- (10) Reports should have an executive summary, and should be signed by the NCC chairperson.
- (11) A copy of the conflict of interest statement should be provided to all NCC members to the WHO/SEARO secretariat.

Country-specific comments and recommendations:

Table India-specific recommendations are presented in 1 and recommendations for other Member States of the SEA Region in Table 2. Based on the recommendations from the third meeting of the SEA-RCCPE in August 2012, the NCCPE grouped the states and union territories of India into three blocks on the basis of polio epidemiology. States that did not report wild poliovirus for more than five years were designated Block 1, Low-risk. States that reported wild poliovirus in the previous 3-5 years were designated Block II, medium-risk. And states that reported wild poliovirus within the past three years or were historically endemic states were designated Block 3, high-risk. The report on Block 1, low-risk states was previously presented at the fourth meeting of SEA-RCCPE in December 2012. The report on Block 2, medium-risk states including Andhra Pradesh, Assam, Haryana, Himachal Pradesh, Jammu & Kashmir, Jharkhand, Maharashtra, Madhya Pradesh, Odisha, Punjab, Rajasthan and Uttarakhand were presented at the fifth meeting of SEA-RCCPE.

Country-specific recommendations below also include comments on phase-1 laboratory containment activities. These activities include the survey and inventory of all national laboratories that contain infectious or potentially infectious polioviruses. The completion of phase-1 laboratory is a requirement for the NCCPE to submit its final national polio-free certification documentation. The final report on the phase-1 laboratory containment activities needs to be completed by December 2013.

Country **Comments and Recommendations** (1) Based on the information presented by the India NCCPE on the 12 states in Block 2, the SEA-RCCPE believes that the AFP surveillance system is capable of detecting polioviruses (WPV/VDPVs) and that there is no circulating poliovirus in these areas. (2) Despite high performing SIAs, the RCC is concerned about population immunity and the accumulation of susceptibles due to poor RI coverage in some areas. (3) India NCC should provide additional information describing population immunity (i.e. vaccination coverage surveys, India (Block II) immunization status of NPAFP cases, sero-surveys) to reassure the RCC that there is a low risk of outbreaks and circulation following importation of WPVs or cVDPVs. (4) The RCC is concerned about the status of phase-1 laboratory containment in India. (5) Completion of phase-I laboratory containment is a requirement for India to submit its national polio-free certification documentation. If not completed and verified by December 2013, the RCC cannot consider the India documentation and the regional polio-free certification will be delayed. India NCC should prepare documentation on Block 3, high-(6) risk states for review at the October 2013 SEA-RCCPE meeting.

Table 1. India Block 2, Medium-risk states specific recommendations

Country	Comments and Recommendations	
Bangladesh	(1) Additional information and/or reasons for poor performance of the AFP surveillance system with regard to timeliness and completeness of reporting should be provided.	
Bang	(2) A description of any plans/strategies for maintaining high population immunity for displaced persons/refugees/ migrants during a natural and/or man-made disaster should be provided.	
	(1) Population data on the under five-year-old population and on mobile and nomadic groups should be confirmed.	
E	(2) An explanation of immunization target population and coverage should be provided.	
Bhutan	(3) A line-list of all AFP cases with diagnoses in the annual update should be included.	
	(4) Additional information on the last polio case in 1986 and AFP surveillance activities through 2012 should be provided.	
	(1) A detailed description of OPV3 dropout rates and any areas with low routine immunization coverage (national/sub-national) should be provided.	
esia	(2) Any additional activities to address low coverage (such as backlog fighting) should be described.	
Indonesia	(3) A description of high-risk areas should be provided and planned interventions, specifically in border areas with Malaysia, Papua New Guinea and Timor-Leste should be discussed.	
	(4) Advocacy for risk mitigation activities (SIAs) and district level prioritization of polio eradication should be ensured.	

Table 2. SEAR country-specific recommendations (excluding India)

	(1) A detailed explanation of the effects of the following issues on the surveillance and immunization programme should be provided:
	reversion to centralization from decentralization
ves	governance and funding
Maldives	 high number of expatriate doctors and high health staff turnover
	(2) Advocacy for explanation of active surveillance should be undertaken in all hospitals.
	(3) NCC meetings and activities should be re-established in 2013.
	(1) Areas of poor access and poor immunization coverage and plans to address them should be described.
Myanmar	(2) Information on the recent changes in the country's routine immunization schedule should be provided and the impact on coverage assessed.
	(3) A detailed description of any risk assessment and cross- border activities should be provided.
	(1) Detailed description of 2012 NID and MR campaign + OPV including coverage and target populations should be furnished.
Nepal	(2) Non-polio AFP rate and a specified rate of GBS should be included.
	(3) Information on-hard-to reach populations and any specific plans to improve coverage should be submitted.

	(1) Further evidence of polio-free status despite low non-polio AFP rate (review for accuracy) should be provided.
Sri Lanka	(2) Explanation of low performing areas (coverage or surveillance) and the plan for improvement should be provided.
Sri	(3) An AFP surveillance review should be discussed and planned in the report.
	(4) Discussions should be held on getting up an active surveillance system.
_	(1) The executive summary should be duly edited, mentioning the significance of Thailand's fully accredited regional reference laboratory.
Thailand	(2) Further information should be provided on the expert review committee's discarded specimen data, clarifying if any case(s) are VAPP.
	(3) Any updated risk assessment for importation should be included.
	(1) A detailed description of areas with low OPV3 coverage and plans for any SIA to increase should be provided.
Timor-Leste	(2) Any additional surveillance or immunization data (independent survey) that would increase confidence in the country polio-free status report should be furnished.
Timo	(3) Details of the specimen collection and transport process and any plans for improvement should be submitted.
	(4) Multi-lingual AFP surveillance guidelines and manuals should be obtained.

6. Recommendations

WHO should follow up the conclusions and recommendations of this meeting and prepare for the sixth meeting of the SEA-RCCPE planned for October 2013 as follows:

(1) A letter should be prepared for the NCCPE on the proceedings of this meeting with conclusions and recommendations.

- (2) A letter should be addressed to the Government of India on the proceedings of this meeting, highlighting the Commission's concerns regarding progress towards phase-1 laboratory containment.
- (3) A meeting should be organized between the RCC Chair, additional members of the RCC and appropriate representatives from the Government of India.
- (4) The polio laboratory task force coordinator should be contacted to follow up on monitoring of progress on the phase-1 laboratory containment and to ensure that there is an update during the sixth meeting of the SEA-RCCPE in October 2013.
- (5) Implementation of the recommendations for the second block and preparation for the third block should be coordinated with the NCCPE.

December 2012	Fourth meeting of the SEA-RCCPE:
	 review of preliminary documentation from India (block 1) and phase-1 laboratory containment plan.
March 2013	Fifth meeting of the SEA-RCCPE:
	 review of 2012 annual updates from Bangladesh, Bhutan, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste;
	review of preliminary documentation from India (block 2) and phase-1 laboratory containment plan.
October 2013	Sixth meeting of the SEA-RCCPE:
	 review of preliminary documentation from India (block 3) and phase-1 laboratory containment plan;
	review of documentation from Democratic People's Republic of Korea and Re-review of documentation from Timor-Leste including phase-1 laboratory containment plans;
	 review of GCC requirements for submission of regional documentation;

Table 3: Timeline for polio certification in the South-East Asia Region

	 review of documentation from all Member States for submission to the GCC.
February 2014	Seventh meeting of the SEA-RCCPE:
	review of 2013 annual updates from Bangladesh, Bhutan, Democratic People's Republic of Korea, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste;
	 review of full certification documentation from India with phase-1 laboratory containment documentation;
	➢ submission of SEA-RCCPE report to the GCCPE.

Annex 1

Agenda

- Polio eradication: Global overview/update
- > Recommendation of Independent Monitoring Board (IMB)
- > Regional update: Eastern Mediterranean Report
- > Preliminary documentation: India Block II (A)
- > Preliminary documentation: India Block II (B)
- > Preliminary documentation: India Block II (C)
- > Report on laboratories containment activities, India
- Annual updates of national documentation and laboratory containment activities on: Bangladesh, Bhutan, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste.
- Conclusions and recommendations

Annex 2 List of participants

RCCPE Chairperson

Dr Supamit Chunsuttiwat Senior Medical Officer Department of Disease Control Ministry of Public Health Bangkok, Thailand

RCCPE Members

Dr Suniti Acharya Executive Director Center for Health Policy Research and Dialogue Kathmandu, Nepal

Dr Anthony Adams Ex Professor of Public Health National Centre for Epidemiology and Population Health Australian National University Avoca Beach, Australia

Dr Abraham Joseph Director The Christian Institute of Health Sciences & Research (CIHSR) Vellore, Tamil Nadu, India

Prof Ismoedijanto Moedjito Professor of Paediatrics Department of Child Health Medical School Airlangga University Surabaya, Indonesia

Dr Ali Jaffar Mohamed Assistant Secretary-General Arab League for Quality in Health Services Muscat Sultanate of Oman

Prof Mahmudur Rahman Director Institute of Epidemiology Disease Control and Research (IEDCR) & National Influenza Centre (NIC) Dhaka, Bangladesh Dr Kyaw Nyunt Sein Fund Management Executive UNOPS Yangon, Myanmar

Dr David Salisbury Director of Immunization Department of Health Richmond House London, United Kingdom

Dr Nalini Withana Virologist Kalubowila, Sri Lanka

NCCPE Chairpersons

Dr Sujarti Jatanasen Advisor Department of Disease Control Ministry of Public Health Nonthaburi, Thailand

Prof MR Khan Director Institute of Child Health & Shishu Sasthya Foundation Dhaka, Bangladesh

Dr Badre Raj Pande President Nepal Health Economics Association Kathmandu, Nepal

Mr Phub Rinchhen Former Chief Administrator Department of Medical Services Institute of Traditional Medicine Services Ministry of Health Thimphu, Bhutan

Prof Sumarmo Poorwo Soedarmo Former Senior Advisor to the Minister of Health on Health Technology Ministry of Public Health Jakarta, Indonesia Dr Abdul Azeez Yoosuf Consultant in Medicine Maya Clinic and Azmi-Naeem Medical Center Malé, Maldives

NCCPE Members/Representatives

Dr Helio Guterres National Hospital of Guido Valadares Dili, Timor-Leste

Dr EGP Haran Public Health Specialist NH-8, Gurgaon, India

Dr Paba Palihawadena Chief Epidemiologist Epidemiological Unit Ministry of Health Colombo, Sri Lanka

Prof Win Min Thit Head, Neuro Medicine University of Medicine Yangon, Myanmar

Laboratory Task Force India

Dr Jagdish Deshpande Director Global Specialized Laboratory Enterovirus Research Centre Mumbai, India

National Polio Surveillance Project (NPSP) India

Dr Sunil Bahl Deputy Project Manager New Delhi, India

Dr Sudhir Joshi Medical Officer, Polio Certification New Delhi, India

WHO Headquarters

Dr Rudolf Tangermann Coordinator Programme Monitoring and Operations Unit Department of Polio Operations and Research Geneva, Switzerland

WHO Maldives

Ms Aminath Shenalin National Professional Officer Programme Implementation & Monitoring Malé, Maldives

Observers-MOH Malé, Maldives

Dr Aishath Aroona Abdulla Epidemiologist Health Protection Agency

Ms Maimoona Aboobakuru Director Communicable Disease Division Health Protection Agency

Ms Nashiya Abdul Gafoor Public Health Programme Officer National Immunization Programme Health Protection Agency

Dr Abdulla Niyaf Senior Consultant in Paediatrics ADK Hospital

Ms Fathimath Rasheedha Public Health Programme Officer Health Protection Agency

Ms Aishath Thimna Latheef Public Health Programme Officer National Immunization Programme Health Protection Agency

Ms Aishath Shudha Laboratory Technologist Indira Gandhi Memorial Hospital

WHO-SEARO

Dr Patrick O'Connor Regional Adviser Immunization and Vaccine Development

Dr Robert D Allison Consultant Immunization and Vaccine Development

Dr Zainul Abedin Khan Technical Officer-Polio Certification Immunization and Vaccine Development The fifth meeting of the South-East Asia Regional Commission for Certification of Polio Eradication (SEA-RCCPE) was held from 4 to 7 March in Malé, Maldives. The primary objective of this Commission is to guide Member States through the certification process for polio eradication through impartial and transparent verification.

The purpose of the meeting was to review the annual reports from Member States and make recommendations to improve documentation for certification. The Region has made tremendous progress towards polio eradication and is currently on track for regional certification in February 2014.



Regional Office for South-East Asia

World Health House Indraprastha Estate, Mahatma Gandhi Marg, New Delhi-110002, India

